Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.

Nicolas Verheyen, Astrid Fahrleitner-Pammer, Burkert Pieske, Andreas Meinitzer, Evgeny Belyavskiy, Julia Wetzel, Martin Gaksch (Co-author), Martin R Grübler, Cristiana Catena, Leonardo A Sechi, Adriana J Van Ballegooijen, Vincent M Brandenburg, Hubert Scharnagl, Sabine Perl, Helmut Brussee, Winfried März, Stefan Pilz, Andreas Tomaschitz

    Research output: Contribution to journalOriginal Articlepeer-review

    21 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)177-186
    JournalJOURNAL OF HYPERTENSION
    Volume34
    Issue number9
    DOIs
    Publication statusPublished - 2016

    Keywords

    • PLACEBO-CONTROLLED TRIAL
    • CARDIOVASCULAR-DISEASE
    • ANGIOTENSIN-II
    • SERUM-CALCIUM
    • HYPERTENSION
    • SECRETION
    • MORTALITY
    • RESPONSES
    • ADENOMA
    • RANGE

    Cite this